Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor - Therapy Letter
2015:81:6;642-644
doi: 10.4103/0378-6323.168328
PMID: 26515857

Tacrolimus for treatment of toxic epidermal necrolysis

Pavitra M Dogra1 , Manas Chatterjee2 , Shekhar Neema2
1 Department of Nephrology, Command Hospital, Kolkata, West Bengal, India
2 Department of Dermatology, Command Hospital, Kolkata, West Bengal, India

Correspondence Address:
Pavitra M Dogra
Department of Nephrology, Fourth Floor, Command Hospital (EC), Alipore, Kolkata - 700 027, West Bengal
India
How to cite this article:
Dogra PM, Chatterjee M, Neema S. Tacrolimus for treatment of toxic epidermal necrolysis. Indian J Dermatol Venereol Leprol 2015;81:642-644
Copyright: (C)2015 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Toxic epidermal necrolysis is an aggressive and progressive skin eruption involving more than 30% of the body surface area and carries a high mortality (30%).[1] The cytotoxic T-cell is believed to play an important role in pathogenesis and is blocked by intravenous immunoglobulin and cyclosporine, agents that are effective in treatment.[2] We report a patient with toxic epidermal necrolysis who was managed using tacrolimus, another drug that shares this action.

A 56-year-old woman was admitted with generalized tonic-clonic seizures. She was known to be hypertensive for 10 years and had proteinuria for which she was being managed by the nephrologist. At admission, her pulse was 128/min, blood pressure was 120/90 mmHg and she was in the postictal phase. She was given injectable phenytoin sodium 20 mg/kg in the emergency room as per the hospital protocol for seizure management. Approximately 4h later, she was noted to have a developing erythematous rash on the face, all limbs, trunk and abdomen that became confluent within the next 8h and vesiculobullous in the ensuing 6h [Figure - 1]a. There was involvement of conjunctival mucosa and buccal mucosa in addition to urethral inflammation. Nikolsky's sign was positive. More than 70% of body surface area was involved. Her laboratory investigations revealed a normal hemogram and serum biochemistry (hemoglobin 12.8 gm/dL, total leukocyte count 14200/mm 3 with polymorphs 76%, eosinophils 10%, blood urea nitrogen 14 mg/dl, serum creatinine 0.8 mg/dl, serum bilirubin 0.8 mg/dl, serum aspartate aminotransferase 14 IU/L, and serum alanine aminotransferase 19 IU/L). Urinalysis showed trace albumin, 2–4 white blood corpuscles, 2–4 red blood corpuscles per high power field; however, no organisms were grown. Her blood pH was 7.23 and serum bicarbonate 16 mmol/L. Score for toxic epidermal necrolysis (SCORTEN score) was 4 (age >40 years; heart rate >120 beats/min, detached surface >10%, serum bicarbonate <20 mmol/L).

Figure 1: (a) Erythema over face with blistering and mucosal involvement. (b) Thirty-six hours after tacrolimus initiation. (c) On day 9, prior to discharge from hospital

Since cyclosporine and intravenous immunoglobulin were unavailable in the hospital, we began treatment with the immediately available oral tacrolimus, 0.12 mg/kg/day in 2 divided doses. In addition, she received 4 L of normal saline daily, intravenous sodium bicarbonate, 80 mEq over 6 h followed by 80 mEq over next 18 h on first day and then 80 mEq per day for 4 days, amlodipine and atenolol for blood pressure control, intermittent Ryle's tube feeds to maintain nutrition and moisturizing eye drops for conjunctival involvement. Her lesions stopped progressing and blistering stopped within 36h of starting treatment with tacrolimus [Figure - 1]b. Re-epithelization started in 72h. Her urine output, hemodynamic and renal parameters were normal. She steadily improved over the next 48h and became ambulant and started taking oral feeds. The dose of tacrolimus was tapered after 3 days, at the rate of 0.5 mg/kg body weight per day. She received tacrolimus for a total duration of 5.5 days. Her skin condition improved considerably [Figure - 1]c and she was discharged 10 days after admission. The disease behavior and its response to tacrolimus is depicted in [Figure - 2].

Figure 2: The disease behavior and its response to tacrolimus

Toxic epidermal necrolysis is a severe illness that may be complicated by sepsis, shock and multiorgan failure and is hence associated with a high mortality. Our patient had a SCORTEN score of 4, indicating a mortality risk of 58.3%.[3]

Cyclosporine has been used in the treatment of toxic epidermal necrolysis.[4],[5] Calcineurin inhibitors such as cyclosporine and tacrolimus act on the cyclophilin pathway to eventually block interleukin-2 receptors, thus inhibiting the T-cell mediated immune pathway. This mechanism has led to their extensive use in renal transplantation. In this setting, tacrolimus is more potent than cyclosporine, has a more favorable cardiovascular risk profile and leads to better long-term renal allograft function after renal transplantation.[6] When administered tacrolimus in the absence of cyclosporine, our patient tolerated the drug well without any gastrointestinal side-effect or renal derangement despite having dehydration. At August 2014 costs in India, the treatment of a 50 kg patient of toxic epidermal necrolysis with cyclosporine 6 mg/kg/day for 7 days (capsule Neoral ® from Novartisd) was INR 2408.00 whereas tacrolimus, 0.12 mg/kg/day for 4 days followed by taper over 2 days (Capsule Tacsant ® from Novartis) was INR 1112.80 making the latter treatment significantly cheaper.

Phenytoin had never been used by our patient earlier. We were unable to find any previous reports of such a short time gap between first exposure to phenytoin and the onset of toxic epidermal necrolysis as was noted in our patient. For this reason, we feel that phenytoin is unlikely to be the cause of Steven Johnson syndrome-toxic epidermal necrolysis. It is likely that one of her other medications precipitated the eruption. However, we cannot exclude the possibility that the parenteral route of administration of a high dose of phenytoin in a setting of renal compromise was responsible for the rapid onset of Steven Johnson syndrome-toxic epidermal necrolysis. We did not undertake rechallenge to establish the causative drug.

Tacrolimus appears to be effective in Steven Johnson syndrome-toxic epidermal necrolysis though studies in larger numbers of patients are needed to substantiate its therapeutic role.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
[Google Scholar]
2.
Fernando SL. The management of toxic epidermal necrolysis. Australas J Dermatol 2012;53:165-71.
[Google Scholar]
3.
Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272-6.
[Google Scholar]
4.
Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, Revuz J, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010;163:847-53.
[Google Scholar]
5.
Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol 2013;79:686-92.
[Google Scholar]
6.
Abou-Jaoude MM, Najm R, Shaheen J, Nawfal N, Abboud S, Alhabash M, et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. Transplant Proc 2005;37:3025-8.
[Google Scholar]

Fulltext Views
269

PDF downloads
93
Show Sections